Background Concurrent platinum-etoposide chemotherapy given in combination with hyperfractionated thoracic radiation therapy (HTRT) in limited disease (LD) small cell lung cancer (SCLC) is associated with a high response rate and significant prolongation of survival. Given these results, the Hellenic Cooperative Oncology Group (HeCOG) performed a multicenter randomized phase II study in patients with LD SCLC to evaluate the timing of HTRT (early vs late) when given concurrently with chemotherapy
Summary
Background Concurrent platinum-etoposide chemotherapy given in combination with hyperfractionated thoracic radiation therapy (HTRT) in limited disease (LD) small cell lung cancer (SCLC) is associated with a high response rate and significant prolongation of survival. Given these results, the Hellenic Cooperative Oncology Group (HeCOG) performed a multicenter randomized phase II study in patients with LD SCLC to evaluate the timing of HTRT (early vs late) when given concurrently with chemotherapy
Patients and methods To be eligible for the study, patients were required to have histologically or cytologically proven LD SCLC, confined to one hemithorax and/or ipsilateral mediastinal or supraclavicular lymphnodes and absence of pleural effusion or controlateral supraclavicular lymphnode involvement. Moreover, patients had to have a good performance status and adequate haematological, liver and renal function Patients with LD SCLC were randomized to receive HTRT either concurrently with the first (Group A) or with the fourth (Group B) cycle of chemotherapy Chemotherapy consisted of carboplatin administered at an AUC of six given as an I.V. 1-hour-infusion immediately followed by etoposide at a dose of 100 mg/m 2 i.v. as a two-hour infusion for three consecutive days every three weeks up to a total of six cycles Prophylactic cranial irradiation was also given to patients achieving a complete response.
Results 42 and 39 patients, were eligible for efficacy evaluation in group A and B respectively The overall response rate was 76% in group A and 92 5% in group B (P = 0 07) with a complete response rate of 40 5% and 56 5%, respectively After a median follow-up of 35 months, time to progression was 9.5 months in group A and 10 5 in group B (NS) while overall median survival was 17 5 and 17 months respectively (NS) The 2-year survival was 36% in group A and 29% in group B (NS) and the 3-year survival 22% and 13%, respectively (NS) The distant relapse rate was 38% in group A and 61% in group B (P = 0.046) Severe grade 3-4 anemia was recorded in 19% of group A and 12.5% of group B (NS), while severe leucopenia was recorded in 35 5% and 20 5% (F = 0.09) and neutropenic fever in 5% and 2.5% (NS), respectively Severe thrombocytopenia did not differ significantly between the two treatment groups being 21 5% and 23%, respectively Severe grade 2-3 esophageal toxicity was 19% in group A and 23% in group B (NS), while grade 3 lung toxicity was 5% and 7 5% (NS), respectively No toxicity-related deaths were recorded
Introduction
Small cell lung cancer (SCLC), which accounts for 20% of all bronchogenic carcinomas, is characterized by its early dissemination at diagnosis, high chemosensitivity and radiosensitivity and rapid relapse [1] . The treatment of choice for limited disease (LD) SCLC is the combination of chemotherapy with thoracic radiation therapy (TRT), which results in a 80%-90% overall response (OR) rate, a 50% complete response (CR) rate, a 16-20 months median survival and a 20%-30% two-year survival rate [2] The current 'gold standard' chemotherapy regimen is the combination of etoposide and a platinum compound (cisplatin or carboplatin) [3] In addition to its efficacy, this chemotherapy combination can also be administered concurrently with TRT with a still acceptable toxicity of intrathoracic organs such as the lung and the esophagus [4] As mentioned, the integration of TRT and chemotherapy in LD SCLC not only reduces local relapses but also prolongs survival This has been proved in numerous studies including our own trial [5] , as well as in the meta-analysis of 16 randomized trials [6] However, the optimal total dose, the volume, the duration and the timing of TRT have not been definitely identified as yet.
SCLC at diagnosis contains cancer cells, which are partially or totally chemoresistant, therefore local or distant relapse and death are inevitable. On the other hand, these cancer cells may still be radiosensitive despite their chemoresistance [7] . It is possible to expect, therefore, that the combination of chemotherapy with TRT can lead to greater efficacy. It is also reasonable to integrate TRT as early as possible to prevent the development of radioresistance. However, there is no definite proof for the hypothesis that early TRT would lead to better efficacy results
It has also been shown that SCLC cell lines, as opposed to normal cells, have little or no 'shoulder region' on the radiation (RT) survival curve. This means that even small doses of RT could kill SCLC cells exponentially while sparing normal cells that have a shoulder and remain intact after their exposure to RT [8] . Therefore, by using combinations of chemotherapy with hyperfractionated TRT (HTRT) in LD SCLC, very satisfactory results with acceptable toxicity can be achieved In a phase II study Johnson et al showed that twice daily concurrent HTRT combined with alternating chemotherapy was associated with an 18-month median survival and a 47% 2-year progression-free survival [9] .
The recently published data by Turrisi et al. [10] clearly indicate that concurrent cisplatin-etoposide with early HTRT is superior to the same combination given concurrently with the early once-daily TRT. Furthermore, concurrent HTRT with carboplatin-etoposide combination followed by etoposide-cisplatin, has shown very promising results in patients who received early HTRT [11] The optimal total dose of TRT, when administered concurrently with chemotherapy, has not been defined yet Choi et al have found that the maximum tolerated dose was 70 Gy if once daily and 45 Gy if twice daily doses were delivered [12] .
Given these principles, HeCOG conducted a randomized phase II study in order to compare the efficacy of early as opposed to late HTRT given concurrently with carboplatin-etoposide chemotherapy in patients with LD SCLC
Patients and methods

Eligibility criteria
Patients entered the study provided they fulfilled all of the following entry criteria Histologically or cytologically proven SCLC, LD disease confined to one hemithorax with involvement of mediastinal and/or ipsilateral supraclavicular lymphnodes Patients with pleural effusion, regardless of the results of cytology, or contralateral supraclavicular lymphnode involvement were excluded from this study Patients must also have performance status 0-2 according to the ECOG scale and an adequate haematological (white blood cell count (WBC) > 3500 cells/ mm 3 , platelets > 100,000 cells/mm 3 and Hb > 10 g/dl), hepatic and renal function (creatinine clearance >60 ml/min)
Those patients who had a history of another malignancy except a curatively resected non-melanoma skin cancer or in situ cervical cancer, as well as those who had been previously treated with systemic chemotherapy or radiation therapy, were excluded from the study
Treatment protocol
Before entering the study, all patients gave their informed consent according to the declaration of Helsinki and to our institutional policies Subsequently, they were centrally randomized al the HeCOG data office to receive HTRT either concurrently with the first (early HTRT, Group A) or with the fourth (late HTRT, Group B) cycle of chemotherapy ( Figure 1) Chemotherapy consisted of carboplatin administered at an area under the curve (AUC) of six, I v by 1-hour infusion on day 1 immediately followed by etoposide at a dose of 100 mg/m 2 i v by two-hour infusion for three consecutive days Treatment chemotherapy was repeated every three weeks up to a total of six cycles HTRT was given at a dose of 1 5 Gy per fraction twice daily up to a total of 45 Gy Patients of group A received HTRT concurrently with the first cycle of chemotherapy while those of group B concurrently with the fourth cycle ( Figure I ) An interval of at least four or, preferably, six hours between the two fractions was mandatory Anterior-posterior fields were used The target volume for the first 30 Gy included the initial tumor area plus the bilateral medustinal and the ipsilateral hilar lymphnodes The ipsilateral supraclavicular area was included in the radiation field, only in case of nodal involvement The spinal cord was limited to 30 Gy The remaining 15 Gy were delivered to the primary tumor In group B, radiation fields were also determined by the initial tumor volume Dose correction was made for lung dishomogeneity Prophylactic cranial irradiation (PCI) was delivered to patients who achieved CR The whole brain was irradiated by using two lateral opposed fields to 20 Gy in five consecutive daily fractions of four Gy each This is a scheme that HeCOG has used for the last ten years without severe acute or long-term CNS toxicity
Dose modifications
Dose modifications were done on the basis of WBC and platelet count as well as on esophageal toxicity If WBC was > 3500 cells/mm 3 and platelets > 100,000 cells/mm 3 on the day of chemotherapy, then the 100% of the scheduled dose was administered Patients with Grade III-IV myelotoxicity on the day of chemotherapy had a treatment delay of up to a maximum of 15 days until recovery when the 75% of the scheduled dose of the drugs was re-administered If Grade 3-4 thrombocytopenia occurred during treatment, then 75% and 50% of the planned dose of carboplatin and etoposide was given respectively In case of grade 3-4 neutropenia, Granulocyte-Colony Stimulating factor (G-CSF) was given prophylactically at all subsequent cycles G-CSF was also administered when grade 3-4 granulocytopenia occurred at any time during TRT The doses of the chemotherapy agents were also adjusted depending on esophageal toxicity Thus, a treatment delay until recovery was performed when grade 3-4 esophageal toxicity appeared Dose modifications and treatment delay was generally discouraged either for HTRTor PCI A treatment delay was permitted for HTRT, only in cases of > grade 3 esophagitis or grade 4 thrombocytopenia and/or neutropenia Asscsment Full blood count, liver and renal function tests were performed before each course of chemotherapy The WHO scale for toxicity grading was used [13] Full blood count and renal function tests were also performed weekly during HTRT A full re-evaluation included full blood count, liver and renal function tests, CT scan of the brain, thorax and abdomen was performed every two cycles of chemotherapy After completion of the treatment, the same re-evaluation was repeated every three months for the first year, every four months for the second year and every six months thereafter Response assessment was performed according to WHO standard criteria [13] No fiberbronchoscopy was performed to assess CR Time to progression (TTP) was calculated from the day of initiation of chemotherapy to the day when progression occurred or recurrence of the disease was documented Survival was calculated from the day of initiation of chemotherapy to the date of death Patients who had no recurrent tumor or were alive on the day of last follow-up were censored
Statistical analysis
This study was designed to test if early HTRT was at least 25% superior to late HTRT in terms of Overall Response Rate (ORR)
• Sample size estimation was based on the assumption that the ORR of late HTRT Group would be 70% Using a two-sided test, a sample size of 84 patients had 80% power to detect a higher ORR by at least 25% for the early HTRT Group at the 5% level of significance Assuming a 3% withdrawal rate, a total of 86 patients were planned to enter the study The study planned an interim analysis when 43 responses had been documented, based on the O'Brien-Fleming [14] boundary values • Fisher's exact test [15] and Kruskal Walhs exact test [16] were used to test differences between the two treatment groups in terms of baseline characteristics of the patients, response and toxicity on an intent-to-treat basis Time to the event distributions, time to progression and overall survival were estimated by the Kaplan-Meier [17] method, and the log-rank test [18] was used for statistical inference For the estimation of the TTP curve, chemotherapy interruptions and deaths from disease without recorded progression were included as events Logistic [18. 19] and Cox [20] regression analysis were used to assess the prognostic value of treatment, age (<60 vs >60 years), gender, PS (0-1 vs 2) and weight loss on ORR, TTP and survival Smoking was not included because it was highly unbalanced, only three non-smokers having been included in the study Backward selection procedure was used to identify the significant variables based on the likelihood ratio test with a threshold value of 10% [21] Significance was determined at the 5% level, where all reported /"-values were two-sided
Results
Patients and tumor characteristics
From December 1993 to November 1999, 86 patients with histologically or cytologically confirmed LD SCLC, entered the study. Almost all patients except seven were male smokers with a good PS. However, five patients were excluded from the analysis, four had pleural effusion regardless of the results of cytology and one adrenal metastasis at study entry. Therefore, 81 patients remained eligible for analysis ( Table 1) . Progress of patients through the various stages of the trial is shown in Figure 2 according to the CONSORT statement [22] .
Treatment characteristics
A total of 242 cycles for Group A and 233 for Group B were respectively given Thirty (71%) patients in Group A and 35 (90%) in Group B respectively received their planned six courses of chemotherapy (Table 2 ). One patient from Group A did not receive any treatment because he voluntarily withdrew from the protocol Seven patients from Group A and 2 from Group B Abbreviations c -cycle, n -number received less than six cycles (range 1-5) of chemotherapy mainly because of patients' refusal to continue chemotherapy due to toxicity Of note, five patients from Group A and two from Group B received more than six cycles (range 8-9) because the physicians considered that these patients continued to respond after completing the sixth cycle. Median relative dose intensity of etoposide was 0 86 in Group A and 0.90 in Group B, respectively. Of note, no difference between the actual radiation volumes delivered in both groups was found, while all patients received their planned dose of HTRT with a median delay of one week only, mainly due to esophagitis.
Toxicity
There was no significant difference in the incidence of Grade 3-4 myelotoxicity between the two treatment Groups (Table 3) . Grade 3-4 anaemia was recorded in 19% and 12.5% of patients for Group A and B, respectively Febrile neutropenia was recorded in 5% and 2.5% of patients from Group A and B, respectively, again without statistically significant differences. No myelotoxic related deaths were recorded in both treatment Groups. Apart from alopecia, which was almost universal for both treatment Groups, and esophageal and lung toxicity, no other serious non-haematological tocixities were recorded The overall esophageal toxicity for Group A was 35.5% with only 2.5% grade 3 toxicity, as opposed to 33.5% for Group B with 18% severe grade 3 toxicity (Table 4 ). The overall lung toxicity was recorded in 24% of patients from Group A with only 5% severe Grade 3 toxicity. In Group B, overall lung toxicity occurred in 20.5% and Grade 3 in 7.5%. These differences were statistically significant only for grade 3 esophageal toxicity which was more prominent in Group B (P = 0.03).
Response
Seventeen patients from Group A and 22 from Group B responded completely with a CR rate of 40 5% and 56.5%, respectively, with no significant difference. The overall response rate, by using the intent-to-treat efficacy analysis, was marginally significant in favor of Group B (76.0%, 95% CI: 61%-88% for Group A vs. 92.5%, 95% CI: 79%-98% for Group B, P = 0.07), respectively (Table 5 ). Two patients from Group A were not evaluated for response due to sudden death and voluntary withdrawal from treatment. The multivanate analysis showed that only the late HTRT treatment was an independent prognostic factor for ORR (odds ratio 3.8, 95% CI: 0.95-15 4, P = 0.06)
TTP and survival
After a median follow-up of 35 months, 32 (76%) patients in Group A and 34 (87%) in Group B have progressed. Median TTP was 9.5 and 10.5 months, respectively (P = 0.6). At the time of the analysis 29 (69%) patients in Group A and 32% (82%) in Group B have died CP = 0.65) with an overall survival (OS) of 17.5 and 17 months, respectively. However, there was a trend for a better two-year (36% vs. 29%, P = 0.42) and three-year (22% vs. 13%, P = 0.32) survival in favor of Group A.
Sixteen (38%) patients in Group A and 24 (61 5%) in Group B, respectively relapsed distantly and this difference was marginally statistically significant (P = 0.046). Finally, the brain relapse rate was 26% for Group A and 33% for Group B, respectively, again without significant difference. The multivariate analysis for TTP and OS showed that only weight loss was an independent inverse prognostic factor (for TTP: hazard ratio 2.1, 95% CI: 1.05-4 6, P = 0.035, for OS-hazard ratio 1.97, 95% CI: 1.002-3.9,/'= 0.05).
Discussion
Cisplatin-etoposide combination chemotherapy, based on a preclinical indication of synergy, has remained, so far, the 'gold standard' treatment for SCLC [3] . The above regimen has substituted cyclophosphamide, doxorubicin, vincristine (CAV), in the concurrent chemo-TRT of LD SCLC due to a lower toxicity of intrathoracic organs, mainly esophagus and lung. In our previous randomized trials, where cisplatin-etoposide was compared with carboplatin-etoposide combination, it was clearly shown that both regimens were equally effective [5] However, the carboplatin and etoposide combination, although more myelotoxic, was more tolerable and could also be given on an outpatient basis For this reason, our group has adopted the carboplatin-etoposide doublet as standard regimen in the treatment of LD SCLC. The radiosensitivity of SCLC, as already mentioned, has been shown in prechnical in vitro [8] and in vivo studies, as well as in clinical studies. Integration of TRT with chemotherapy in LD SCLC has been shown to improve survival in several clinical studies, as well as in a meta-analysis of 13 randomized trials. In the latter analysis, the administration of TRT led to a 14% reduction in the mortality rate (P = 0.001) corresponding to a 5% increase in the 3-year survival rate [6] . Furthermore, the meta-analysis did not find any difference regarding the timing of TRT. It should be emphasized, however, that none of the patients included in this meta-analysis received a cisplatin-etoposide combination, which can be given concurrently with a relatively full dosis of TRT and less morbidity, as opposed to doxorubicin-based or cyclophosphamide-based chemotherapy.
Despite the theoretical advantages of early TRT, no solid data have definitely confirmed the above hypothesis. The randomized Canadian study conducted by Murray et al in which CAV was alternated with cisplatin-etoposide combination, showed that early TRT in the combined modality treatment of LD SCLC is superior to late TRT [23], Furthermore, Bonner et al. have shown that when TRT is delayed, no benefit from HTRT is achieved as compared to a conventional once daily dose [24] Similarly, Takada et al. [25] showed that it is better to give TRT with the first cycle of chemotherapy rather than with the fourth cycle Conversely, Perry et al. found superior results when TRT is given with the fourth rather than with the first cycle of chemo- . Finally, the Danish Group [27] found no difference in response rate, median and 2-year survival rates among patients who received TRT with the first or the fourth cycle of chemotherapy Our study is unique in the setting of a concurrent chemo-HTRT trial of LD SCLC because a) we used a carboplatin-etoposide combination instead of cisplatinetoposide and b) we compared early to late HTRT directly. The total dose of HTRT delivered was 45 Gy which, according to the studies published by Choi et al., is considered to be the maximum tolerated dose [12] .
I-
One should admit that the ORR as primary efficacy endpoint of the study, was not the optimal choice. The latter included a lot of possible bias mainly due to the modifications induced by the radiation therapy. However, the choice of overall survival as the ultimate significant endpoint, would require a much longer sample size in order to detect a clinically significant difference
The achieved ORR and CR with combined modality were very satisfactory in both groups of our study. These results compare favourably with those of similar studies. Johnson et al. reported a 97% ORR with 59% CR by using cisplatin-etoposide combination chemotherapy alternated by HTRT given for five consecutive days on weeks 1, 2 and 3 of chemotherapy, followed by late intensification treatment with high doses of cyclophosphamide-etoposide in patients achieved CR [9] . On the other hand, Turrisi found a 87% ORR with 56% CR in the group of patients who received cisplatin-etoposide concurrently with early HTRT [10] Finally, in a recent phase II study conducted by Hugli et al., where up-front HTRT was given two weeks before initiation of chemotherapy with cisplatin-etoposide, ORR was 90% with a 60% CR [28] . A recent study conducted by the Japan Clinical Oncology Group, where HTRT was given early or late in combination with cisplatin-etoposide, also showed marginally better results in favor of early HTRT [29] . Median and five-year survival was 27.2 months and 24% in the early HTRT group compared to 19.5 months and 18%, respectively, in the late HTRT group It is interesting to note that no significant esophageal toxicity was reported in this study Finally in Jeremic's [11] study median survival was superior in the early HTRT group (34 vs. 26 months), while toxicity was acceptable.
Although response rates were higher in group B, median survival was almost identical in both groups of our study Moreover, two-and three-year survival rates did not differ significantly between the two treatment groups. The observed discrepancy is not easily explained and might be due, at least partially, to the quality of staging procedure, the lack of repeated bronchoscopy to confirm CR and the difficulty of differentiating radiation-induced lung lesions from tumors Distant metastases occurred more frequently in the late HTRT group (38% vs 61.5%, P = 0.046).
Of note, brain relapse rate was 26% and 33% for Group A and B, respectively, with no statistically significant difference. These results compare favourably with other studies such as the Johnson's trial where brain metastases occurred in 28% of the patients It has been well established that PCI administration in patients with LD SCLC decreases the risk of brain metastases and increases the rate of disease-free survival and overall survival [30] . Toxicity in our study was acceptable. There was a trend for more severe anaemia, leucopema and neutropenic fever in the group of patients who received early HTRT, while severe thrombocytopenia was equally distributed in both groups. These results are not easily interpretable. Initial bone marrow involvement could be, at least partially, the reason for the observed higher myelosuppresion in patients who received early HTRT. However, no bone marrow biopsy or aspiration, as staging procedure, was performed In general, myelosuppression in our study was less severe as compared to Turrisi's and Hugh's studies. This might be due to the fact that G-CSF was used in 71 5% and 51.5% of the patients of Group A and B respectively, a difference which was nearly statistically significant (P = 0.07) Apart from alopecia, which was almost universal in both treatment groups, the most frequent non-haematological toxicity was of the lung and esophagus. Grade 3 lung toxicity, which was 5% and 7.5% for Group A and B, respectively, did not differ significantly and it was almost similar to the study of Turrisi who reported a 6% grade 3-5 lung toxicity in the group of early HTRT. Grade 3 esophageal toxicity was more prominent and significantly higher in Group B (f = 0.03), perhaps because these patients had already received three more doses of chemotherapy that might influence their tolerance to the subsequent chemo-radiotherapy. In the Turrisi's study grade 3-4 esophageal toxicity was recorded in 33% of the patients in the HTRT Group. The differences in toxicity between these studies could be due to the different drugs (cisplatin vs. carboplatin) and different doses (etoposide 120 mg/m 2 vs. 100 mg/m 2 dl-3) that were used. However, in Hugh's study, where etoposide was administered at a dose of 100 mg/m 2 , esophageal grade 3-4 toxicity was again higher (38%) than in our study. It has been published that when carboplatin-etoposide instead of cisplatin-etoposide combination is used with or without concurrent radiation therapy, esophageal toxicity is still acceptable [11] . Of note, no toxic related deaths because of myelosuppression, esophagitis or lung toxicity were recorded in our study.
In conclusion, concurrent carboplatin-etoposide combination with HTRT can result in a high response and survival rate The toxicity of this promising therapeutic approach was acceptable. Early integration of HTRT has not been proven to be definitely superior in our study. Comparative randomized phase III studies, with larger numbers of patients may answer this question. 
